ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 573,76
-0,77%
Dow Jones
40 211,72
0,53%
DAX
18 501,82
-0,53%
Brent Oil
83,105
-1,46%
Bitcoin
63 704,57
-1,77%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
20/11/202322h30Business WireTeva to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
17/11/202314h30Business WireTeva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
16/11/202313h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
13/11/202314h10GlobeNewswire Inc.Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
13/11/202314h00Business WireTeva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202313h00Business WireTeva Reports Third Quarter 2023 Financial Results and Increases Revenue GuidanceNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202322h30Business WireTeva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients BusinessNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202313h00Business WireTeva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202300h31Business WireUZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet PsychiatryNYSE:TEVATeva Pharmaceutical Industries Ltd
25/10/202315h00Business WireTeva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
18/10/202313h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
17/10/202317h51Business WireTeva UNITE-Studie der Phase IV zeigt: AJOVY® (fremanezumab) reduzierte Migräne-Anfälle und depressive Symptome bei Migräne-Patienten mit schwerer depressiver StörungNYSE:TEVATeva Pharmaceutical Industries Ltd
17/10/202317h51Business WireL’étude de phase IV UNITE de Teva montre qu’AJOVY® (fremanezumab) réduit les crises de migraine et les symptômes de dépression chez les personnes migraineuses souffrant d’un trouble dépressif majeurNYSE:TEVATeva Pharmaceutical Industries Ltd
17/10/202307h30Business WireTeva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive DisorderNYSE:TEVATeva Pharmaceutical Industries Ltd
06/10/202322h30Business WireTeva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
04/10/202307h57Dow Jones NewsSanofi, Teva Collaborate on Inflammatory Bowel Disease DrugNYSE:TEVATeva Pharmaceutical Industries Ltd
04/10/202307h07Business WireSanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
28/09/202322h05Business WireTeva Announces Changes to Executive Management TeamNYSE:TEVATeva Pharmaceutical Industries Ltd
06/09/202322h30Business WireTeva to Present at the 21st Annual Morgan Stanley Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
06/09/202314h00Business WireTeva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
24/08/202313h30Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
22/08/202313h19IH Market NewsTuesday’s Wall Street Highlights: Baidu, Lowe’s, American Airlines, S&P Global, and moreNYSE:TEVATeva Pharmaceutical Industries Ltd
21/08/202322h00Business WireTeva Settles Price Fixing Charges With U.S. DOJNYSE:TEVATeva Pharmaceutical Industries Ltd
03/08/202313h33IH Market NewsThursday’s Wall Street Highlights: Anheuser-Busch InBev, Apple, Hasbro, Sunrun and moreNYSE:TEVATeva Pharmaceutical Industries Ltd
02/08/202322h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:TEVATeva Pharmaceutical Industries Ltd
02/08/202313h00Business WireTeva Reports Second Quarter 2023 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
27/07/202314h00Business WireTeva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business DevelopmentNYSE:TEVATeva Pharmaceutical Industries Ltd
24/07/202310h00Business WireTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars PartnershipNYSE:TEVATeva Pharmaceutical Industries Ltd
05/07/202322h30Business WireTeva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
01/07/202311h37Business WireTevas dritte Zwischenanalyse der PEARL-Real-World-Studie zu AJOVY® (Fremanezumab) zeigt anhaltende langfristige Wirksamkeit bei der Verringerung von Häufigkeit, Dauer und Schwere der Anfälle bei Patienten mit chronischer und episodischer MigräneNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
CAP
Capgemini
EU
PX1
CAC 40
USI
USTECH100
US Tech 100
EU
DG
Vinci
EU
RI
Pernod Ricard
EU
CS
Axa
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
NYSE
MRK
Merck
NYSE
KO
Coca Cola
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
EU
LR
Legrand
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés